CD19 and B-cell non-Hodgkin lymphoma: A phase I trial of allogeneic CD19‐CAR‐DNTs (RJMty19) in B‐cell lymphoma reported no ≥G3 CRS, ICANS, GvHD or DLTs and all high‐dose participants achieved responses.173